Base Therapeutics
Advanced cell and gene editing solutions targeting a range of cancers, from lung and liver to glioma and hematological tumors.
Advanced cell and gene editing solutions targeting a range of cancers, from lung and liver to glioma and hematological tumors.
Base Therapeutics is a biotechnology and pharmaceutical startup that focuses on advanced cell and gene editing solutions for a wide range of cancers, including lung, liver, glioma, and hematological tumors. The company's platform includes natural killer cell genetic engineering and other cell therapy products. Founded in 2021, the company recently secured a Series A investment on 16 January 2023 from notable investors including HighLight Capital, Baidu Venture, and Sincere Capital. Base Therapeutics demonstrates promising potential in the crucial field of cancer treatment, making it an attractive prospect for venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 6 |
|
16 Jan 2023 |
No recent news or press coverage available for Base Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.